1. Phenotypic Biomarkers of Aqueous Extracellular Vesicles from Retinoblastoma Eyes.
- Author
-
Amacker A, Peng CC, Jiang N, Sirivolu S, Higa N, Stachelek K, Reiser B, Kuhn P, Cobrinik D, Neviani P, Berry JL, Jovanovic-Talisman T, and Xu L
- Subjects
- Humans, Cell Line, Tumor, Tetraspanin 29 metabolism, Male, Uveal Neoplasms metabolism, Uveal Neoplasms pathology, Uveal Neoplasms genetics, Female, Retinal Neoplasms metabolism, Retinal Neoplasms pathology, Tetraspanin 30 metabolism, Tetraspanin 28 metabolism, Melanoma metabolism, Melanoma pathology, Melanoma diagnosis, Child, Preschool, Phenotype, Infant, Child, Glaucoma metabolism, Glaucoma pathology, Retinoblastoma metabolism, Retinoblastoma pathology, Extracellular Vesicles metabolism, Aqueous Humor metabolism, Biomarkers, Tumor metabolism, AC133 Antigen metabolism
- Abstract
Recent advancements in aqueous humor (AH) cell-free DNA (cfDNA) genomics have opened new avenues for ex vivo molecular profiling of retinoblastoma (RB), the most common pediatric intraocular malignancy, where biopsy is typically prohibited. While these insights offer a genetic blueprint of the tumor, they lack multi-omic molecular phenotyping, which is essential for understanding the functional state. Extracellular vesicles (EVs), naturally present in AH, are promising by offering time-resolved phenotypic information. We employed multiplex bead-based flow cytometry and Single Extracellular Vesicle Nanoscopy (SEVEN) to analyze EV phenotypes in AH from a cohort of five RB, with three uveal melanoma (UM) and two age-matched glaucoma (GLC) samples serving as controls. The studies identified CD133-enriched EVs uniquely in RB AH, absent in both GLC and UM AH. This was corroborated by further analysis of five RB cell lines, including two commercial (Y79, Weri) and three in-house developed lines, confirming CD133 enrichment and supporting its role as an RB-specific EV marker. Single-vesicle analysis demonstrated a strong association of CD133 with CD81 and CD63, with minimal CD9 presence. These results, validated through complementary techniques, position CD133 as a critical marker in RB-derived EVs, paving the way for enhanced multi-omic RB characterization and potential advancements in clinical diagnostics.
- Published
- 2024
- Full Text
- View/download PDF